Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NBIX
NBIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NBIX News
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
3d ago
seekingalpha
First Expert Recommendations for Glucocorticoid Dose Reduction Published
4d ago
PRnewswire
New Algorithms Aid in Reducing Hormone Doses for CAH Patients
4d ago
Newsfilter
Neurocrine Biosciences Reports Record Q1 2026 Earnings Driven by INGREZZA
4d ago
seekingalpha
Neurocrine Biosciences Q1 Earnings Exceed Expectations
5d ago
seekingalpha
Investigation Alerts for Multiple Company Mergers
5d ago
Globenewswire
Neurocrine Biosciences Q1 Earnings Announcement Scheduled
6d ago
seekingalpha
Neurocrine Biosciences Releases Survey Findings on Tardive Dyskinesia Impact
6d ago
PRnewswire
Survey Reveals Tardive Dyskinesia's Impact on Employment
6d ago
Newsfilter
Neurocrine Initiates Phase 1 Study for Obesity Treatment
6d ago
PRnewswire
Neurocrine Initiates Phase 1 Study for NBIP-'2118 Weight Loss Therapy
6d ago
Newsfilter
Neurocrine Presents New Two-Year Data on CAH Treatment
May 01 2026
PRnewswire
Investigation Alerts for Multiple Mergers
Apr 27 2026
Globenewswire
Investigations into Multiple Medical Company Mergers
Apr 15 2026
Globenewswire
Neurocrine's INGREZZA Shows Superior Treatment Persistence in Real-World Analysis
Apr 15 2026
NASDAQ.COM
INGREZZA Shows Superior Treatment Persistence in Tardive Dyskinesia
Apr 14 2026
PRnewswire
Show More News
